|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
The observation that the insulinotropic actions of GLP-1 are reduced in type 2 diabetes mellitus (T2DM) led to the development of incretin-based therapies - GLP-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors - for the treatment of hyperglycaemia in these patients.
|
28869249 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
There have been several new treatment approaches established for the management of hyperglycemia in type 2 diabetes (T2D), with treatment guidelines listing both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and basal insulin therapies as considerations for patients who have failed to control their blood glucose with oral antidiabetic agents.
|
29492243 |
2018 |
|
Hyperglycemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
There is no evidence that the GLP-1R agonists cause a major reduction in HbA1c, or have a major effect on hypo- or hyperglycemia in subjects with TD1M.
|
30234389 |
2018 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
These characteristics make GLP-1 receptor agonists attractive agents to treat dysglycaemia in perioperative or high-dependency hospital settings, where glycaemic variability and hyperglycaemia are associated with poor prognosis.
|
31141838 |
2019 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study aims to erase the likelihood of hyperglycaemia and to remain the inherent catabolic effects through improving GLP-1R activation and deteriorating GCGR activation so as to lower the bodyweight and show diabetes-protective effects.
|
28772236 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
To evaluate whether exposure to GLP-1 receptor agonist Liraglutide could modulate pro-atherogenic alterations previously observed in endothelial cells obtained by women affected by gestational diabetes (GD), thus exposed in vivo to hyperglycemia, oxidative stress, and inflammation and to evaluate endothelial microvesicle (EMV) release, a new reliable biomarker of vascular stress/damage.
|
28753251 |
2017 |
|
Hyperglycemia
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
To investigate alterations in gene expression resulting from incubation with GLP-1 (7-36) or hyperglycaemia, the RNA expression levels of miR-23a, PGC-1α, Bak, Bax and UCP2 were quantified using real-time PCR.
|
26315270 |
2015 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Treatment with an N2 supplement in combination with three soluble factors (glucagon-like peptide-1 [GLP-1] receptor agonist, notch inhibitor, and transforming growth factor-β [TGF-β] inhibitor) enhanced liver-to-pancreas transdifferentiation based on the following findings: i) the incidence of c-peptide-positive cells increased by approximately 1.2-fold after the aforementioned treatment; ii) the c-peptide expression level in the treated cells increased by approximately 12-fold as compared with the level in the untreated cells; iii) the treated cells secreted insulin in a glucose-dependent manner, whereas the untreated cells did not; and iv) transplantation of treated-transdifferentiated cells into streptozotocin-induced immunodeficient diabetic mice led to the amelioration of hyperglycemia.
|
29768476 |
2018 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
We analyzed the impact of PARP-1 inhibition on <i>C. elegans</i> health in the setting of hyperglycemia and on glucose-stimulated GLP-1 secretion in human intestinal cells.
|
29392078 |
2018 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
We hypothesized that the downregulation of GLP-1R by hyperglycemia might reduce the renal-protective effects of GLP-1R agonists in diabetic nephropathy (DN).
|
31136032 |
2019 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
We investigated whether oral administration of human commensal bacteria engineered to secrete GLP-1(1-37) could ameliorate hyperglycemia in a rat model of diabetes by reprogramming intestinal cells into glucose-responsive insulin-secreting cells.
|
25626737 |
2015 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
[6]-Gingerol, from Zingiber officinale, potentiates GLP-1 mediated glucose-stimulated insulin secretion pathway in pancreatic β-cells and increases RAB8/RAB10-regulated membrane presentation of GLUT4 transporters in skeletal muscle to improve hyperglycemia in Lepr<sup>db/db</sup> type 2 diabetic mice.
|
28793909 |
2017 |